Clinical Trials · NCT07767175
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 142
- Start date
- Aug 2026
- Locations
- 2 sites, United States
- Primary endpoint
- Part A: Number of treatment emergent adverse events (TEAE)